-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
VBI Vaccines (NASDAQ:VBIV) Stock Crosses Below 200-Day Moving Average of $1.13
VBI Vaccines (NASDAQ:VBIV) Stock Crosses Below 200-Day Moving Average of $1.13
VBI Vaccines Inc. (NASDAQ:VBIV – Get Rating)'s stock price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.13 and traded as low as $0.85. VBI Vaccines shares last traded at $0.87, with a volume of 810,237 shares changing hands.
Analyst Upgrades and Downgrades
Separately, Raymond James decreased their price target on VBI Vaccines from $6.00 to $5.00 and set a "strong-buy" rating on the stock in a report on Tuesday, August 9th.
Get VBI Vaccines alerts:VBI Vaccines Stock Down 1.6 %
The company has a 50-day simple moving average of $0.94 and a 200 day simple moving average of $1.13. The company has a market cap of $224.55 million, a P/E ratio of -2.23 and a beta of 1.86. The company has a current ratio of 2.29, a quick ratio of 2.19 and a debt-to-equity ratio of 0.20.
VBI Vaccines (NASDAQ:VBIV – Get Rating) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.11). The business had revenue of $0.35 million during the quarter, compared to the consensus estimate of $0.70 million. VBI Vaccines had a negative net margin of 15,391.36% and a negative return on equity of 75.37%. On average, equities analysts anticipate that VBI Vaccines Inc. will post -0.37 EPS for the current year.Hedge Funds Weigh In On VBI Vaccines
A number of hedge funds and other institutional investors have recently made changes to their positions in VBIV. State Street Corp grew its position in shares of VBI Vaccines by 31.1% during the 1st quarter. State Street Corp now owns 16,216,811 shares of the biopharmaceutical company's stock worth $26,920,000 after buying an additional 3,844,698 shares in the last quarter. Millennium Management LLC grew its position in shares of VBI Vaccines by 211.7% during the 2nd quarter. Millennium Management LLC now owns 1,780,752 shares of the biopharmaceutical company's stock worth $1,440,000 after buying an additional 1,209,393 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of VBI Vaccines by 358.7% during the 2nd quarter. Renaissance Technologies LLC now owns 789,500 shares of the biopharmaceutical company's stock worth $638,000 after buying an additional 617,400 shares in the last quarter. Frontier Wealth Management LLC grew its position in shares of VBI Vaccines by 1,571.7% during the 1st quarter. Frontier Wealth Management LLC now owns 601,800 shares of the biopharmaceutical company's stock worth $951,000 after buying an additional 565,800 shares in the last quarter. Finally, Bank of America Corp DE grew its position in shares of VBI Vaccines by 88.9% during the 1st quarter. Bank of America Corp DE now owns 809,425 shares of the biopharmaceutical company's stock worth $1,343,000 after buying an additional 380,839 shares in the last quarter. Institutional investors own 39.96% of the company's stock.
About VBI Vaccines
(Get Rating)
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.
Recommended Stories
- Get a free copy of the StockNews.com research report on VBI Vaccines (VBIV)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.
VBI Vaccines Inc. (NASDAQ:VBIV – Get Rating)'s stock price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.13 and traded as low as $0.85. VBI Vaccines shares last traded at $0.87, with a volume of 810,237 shares changing hands.
VBI Vaccines Inc.(納斯達克代碼：VBIV-GET Rating)的股價在週五的交易中跌破200日移動均線，200日移動均線切入位為1.13美元，最低交易價格為0.85美元。VBI Vaccines的股票最新報0.87美元，成交量為810,237股。
Analyst Upgrades and Downgrades
分析師升級和下調評級
Separately, Raymond James decreased their price target on VBI Vaccines from $6.00 to $5.00 and set a "strong-buy" rating on the stock in a report on Tuesday, August 9th.
另外，雷蒙德·詹姆斯將VBI疫苗的目標價從6.00美元下調至5.00美元，並在8月9日(星期二)的一份報告中對該股設定了“強勢買入”評級。
VBI Vaccines Stock Down 1.6 %
VBI疫苗股價下跌1.6%
The company has a 50-day simple moving average of $0.94 and a 200 day simple moving average of $1.13. The company has a market cap of $224.55 million, a P/E ratio of -2.23 and a beta of 1.86. The company has a current ratio of 2.29, a quick ratio of 2.19 and a debt-to-equity ratio of 0.20.
該公司的50日簡單移動均線切入位在0.94美元，200日簡單移動均線切入位在1.13美元。該公司市值為2.2455億美元，市盈率為-2.23，貝塔係數為1.86。該公司的流動比率為2.29，速動比率為2.19，債務權益比率為0.20。
Hedge Funds Weigh In On VBI Vaccines
對衝基金參與VBI疫苗
A number of hedge funds and other institutional investors have recently made changes to their positions in VBIV. State Street Corp grew its position in shares of VBI Vaccines by 31.1% during the 1st quarter. State Street Corp now owns 16,216,811 shares of the biopharmaceutical company's stock worth $26,920,000 after buying an additional 3,844,698 shares in the last quarter. Millennium Management LLC grew its position in shares of VBI Vaccines by 211.7% during the 2nd quarter. Millennium Management LLC now owns 1,780,752 shares of the biopharmaceutical company's stock worth $1,440,000 after buying an additional 1,209,393 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of VBI Vaccines by 358.7% during the 2nd quarter. Renaissance Technologies LLC now owns 789,500 shares of the biopharmaceutical company's stock worth $638,000 after buying an additional 617,400 shares in the last quarter. Frontier Wealth Management LLC grew its position in shares of VBI Vaccines by 1,571.7% during the 1st quarter. Frontier Wealth Management LLC now owns 601,800 shares of the biopharmaceutical company's stock worth $951,000 after buying an additional 565,800 shares in the last quarter. Finally, Bank of America Corp DE grew its position in shares of VBI Vaccines by 88.9% during the 1st quarter. Bank of America Corp DE now owns 809,425 shares of the biopharmaceutical company's stock worth $1,343,000 after buying an additional 380,839 shares in the last quarter. Institutional investors own 39.96% of the company's stock.
一些對衝基金和其他機構投資者最近改變了他們在VBIV的頭寸。道富集團在第一季度持有的VBI疫苗股票增加了31.1%。道富集團目前持有這家生物製藥公司16,216,811股股票，價值26,920,000美元，上一季度又購買了3,844,698股。千禧管理有限責任公司在第二季度增持了211.7%的VBI疫苗股份。Millennium Management LLC現在擁有這家生物製藥公司1,780,752股股票，價值1，44萬美元，上個季度又購買了1,209,393股。復興科技有限公司在第二季度將其在VBI疫苗公司的股票頭寸增加了358.7%。復興科技有限責任公司現在持有這家生物製藥公司78.95萬股股票，價值63.8萬美元，上個季度又購買了61.74萬股。FronTier Wealth Management LLC在第一季度將其在VBI疫苗股份的頭寸增加了1,571.7%。FronTier Wealth Management LLC現在擁有601,800股這家生物製藥公司的股票，價值951,000美元，上個季度又購買了565,800股。最後，美國銀行DE在第一季度將其在VBI疫苗公司的股票頭寸增加了88.9%。美國銀行DE現在持有809,425股這家生物製藥公司的股票，價值1,343,000美元，此前在上個季度又購買了380,839股。機構投資者持有該公司39.96%的股份。
About VBI Vaccines
關於VBI疫苗
(Get Rating)
(獲取評級)
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.
VBI疫苗公司是一家生物製藥公司，開發和銷售用於治療傳染病和免疫腫瘤學的疫苗。該公司提供一種預防性乙肝疫苗Sci-B-Vac。它還參與VBI-2601(BRII-179)的開發，VBI-2601(BRII-179)是治療慢性乙肝感染的免疫治療候選藥物。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on VBI Vaccines (VBIV)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- 免費獲取StockNews.com關於VBI疫苗的研究報告(VBIV)
- MarketBeat：回顧一週9/5-9/9
- 為網絡安全股創紀錄的季度做準備
- 汽車市場正在緩慢復甦，這些股票可能表現優異
- DocuSign是否即將發生重大逆轉？
- 石油和天然氣股票：投資可再生能源的安全途徑
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.
每天收到VBI疫苗的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對VBI疫苗和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧